Observing the effects of intra-arterial therapies for liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify the optimal conditions for positive outcomes in patients receiving intra-arterial therapy (IAT) for primary liver cancers, specifically Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Researchers will collect and analyze both retrospective and prospective data from participants at the IRCCS Azienda Ospedaliera Universitaria in Bologna. The study will evaluate clinical and radiological traits, including imaging assessments, to understand treatment responses and potential complications. The study expects to enroll approximately 3,300 participants over a five-year period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosis of Hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) and clinical indication to receive or have already received one of the following treatments:

  * Trans-arterial embolization (TAE),
  * Transarterial chemoembolization (TACE),
  * Transarterial radioembolization (TARE)
  * Drug-eluting beads chemoembolization (DEB-TACE)
* Age over 18
* To give informed consent

Exclusion Criteria:

* shunt of gastro intestinal arteries that cannot be embolized
* metastasis spread outside of the liver
* liver failure

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Cristina Mosconi, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Cristina Mosconi, MD
• Email: cristina.mosconi@aosp.bo.it
• Phone: 0039 3498496325

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TACE plus SBRT before liver transplant for hepatocellular carcinoma

  This study tests whether adding SBRT to standard TACE helps liver transplant patients with hepatocellular carcinoma see better outcomes.

  Recruiting AIO-Studien-gGmbH · München · NCT07924943

• Personalized 3D-printed liver models to pick adjuvant therapy after liver cancer surgery

  Doctors test whether a patient’s own 3D-bioprinted liver model can help choose the best additional treatment to lower the chance of cancer coming back after liver surgery.

  Recruiting The University of Hong Kong · Hong Kong · NCT07839767

• Real-world view of systemic therapies for advanced HCC at a single center

  This study looks at how patients with advanced hepatocellular carcinoma respond to systemic treatments in real-world practice at Mansoura University Hospitals.

  Recruiting Mansoura University · Al Mansurah, Dakahlia Governorate · NCT07814014

• Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen

  This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07811687

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.